Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $1.4 million.

  • CytomX Therapeutics' Share-based Compensation fell 3062.66% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year decrease of 1954.17%. This contributed to the annual value of $7.7 million for FY2024, which is 1039.96% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Share-based Compensation of $1.4 million as of Q3 2025, which was down 3062.66% from $1.4 million recorded in Q2 2025.
  • CytomX Therapeutics' Share-based Compensation's 5-year high stood at $4.5 million during Q2 2022, with a 5-year trough of $1.2 million in Q3 2023.
  • Moreover, its 5-year median value for Share-based Compensation was $2.4 million (2023), whereas its average is $2.5 million.
  • As far as peak fluctuations go, CytomX Therapeutics' Share-based Compensation crashed by 5450.83% in 2023, and later soared by 6272.43% in 2024.
  • CytomX Therapeutics' Share-based Compensation (Quarter) stood at $3.5 million in 2021, then decreased by 27.48% to $2.6 million in 2022, then dropped by 0.7% to $2.6 million in 2023, then fell by 26.18% to $1.9 million in 2024, then decreased by 26.54% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.4 million for Q2 2025, and $2.0 million during Q1 2025.